tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Edward Nash, 175 are a BUY (89.74%), 18 are a HOLD (9.23%), 2 are a SELL (1.03%).
Analyst Edward Nash, currently employed at CANACCORD, carries an average stock price target met ratio of 49.98% that have a potential upside of 43.73% achieved within 293 days.
Edward Nash’s has documented 380 price targets and ratings displayed on 42 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on AKRO, Akero Therapeutics at 08-Oct-2025.
Analyst best performing recommendations are on BLUE (BLUEBIRD BIO).
The best stock recommendation documented was for BLUE (BLUEBIRD BIO) at 6/6/2017. The price target of $1398.96 was fulfilled within 1 day with a profit of $127.57 (10.03%) receiving and performance score of 100.34.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
$3
$2.89 (2627.27%)
$10
6 years 11 months 16 days ago
(12-Nov-2018)
0/5 (0%)
$1.07 (55.44%)
Buy
$3
$2.89 (2627.27%)
$22
6 years 11 months 17 days ago
(11-Nov-2018)
0/3 (0%)
$1 (50.00%)
Hold
$3
$2.89 (2627.27%)
$19
6 years 11 months 17 days ago
(11-Nov-2018)
0/5 (0%)
$1 (50.00%)
Hold
6 years 11 months 19 days ago
(09-Nov-2018)
1/4 (25%)
$8.57 (47.07%)
31
Hold
$8
6 years 11 months 20 days ago
(08-Nov-2018)
1/6 (16.67%)
$4.75 (146.15%)
40
Which stock is Edward Nash is most bullish on?
Which stock is Edward Nash is most reserved on?
What Year was the first public recommendation made by Edward Nash?
